The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 46, Issue 12, 2005, Pages 1749-1753

  Kuliszkiewicz Janus, M ^a   Malecki R ^a   Zoltaszek A ^a   Zastawny, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

ICTP; Multiple myeloma; Osteocalcin; Waldenstr m's macroglobulinemia

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OSTEOCALCIN;

ADULT; ARTICLE; BONE DISEASE; BONE RADIOGRAPHY; BONE TURNOVER; CANCER STAGING; CELL FUNCTION; CONTROLLED STUDY; DENSITOMETRY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WALDENSTROEM MACROGLOBULINEMIA;

BIOLOGICAL MARKERS; BONE DISEASES; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOCALCIN; PEPTIDES; REFERENCE VALUES; WALDENSTROM MACROGLOBULINEMIA;

EID: 32144435917     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500232428     Document Type: Article

References (19)

1. Kyle, R. (1975) Multiple myeloma: Review of 869 cases Mayo Clinic Proceedings, 50, pp. 29 - 40.
2. Bataille, R and Chappard, D and Marcelli, C and Dessauw, P and Sany, J and Baldet, P and Alexandre, C. (1989) Mechanism of bone destruction in multiple myeloma: The importance of unbalanced process in determining the severity of lytic bone disease Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology, 7, pp. 1909 - 1914.
3. Calvo, M and Eyre, D and Gundberg, C. (1996) Molecular basis and clinical application of biological markers of bone turnover Endocrine Reviews, 17, pp. 333 - 368.
4. Noguchi, M and Noda, S. (2001) Pyridinolone cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer The Journal of Urology, 166, pp. 1106 - 1110.
5. Horiguchi, T and Tachikawa, S and Kondo, R and Hirose, M and Teruya, S and Ishibashi, A and Banno, K. (2000) Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer Japanese Journal of Clinical Oncology, 30, pp. 174 - 179.
6. Durie, B and Salmon, S. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer, 36, pp. 842 - 854.
7. Carlson, K and Larsson, A and Simonsson, B and Turesson, I and Westin, J and Ljunghall, S. (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/ creatinine (DPD) and serum ICTP, and an evaluation of the DPD/ osteocalcin and ICTP/osteocalcin ratios European Journal of Haematology, 62, pp. 300 - 306.
8. Peest, D and Deicher, H and Fett, W and Harms, P and Braun, H and Planker, M and (1996) Pyridinum cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy - a pilot study of the German Myeloma Treatment Group (GMTG) European Journal of Cancer, 32A, pp. 2053 - 2057.
9. Jakob, C and Zavrski, I and Heider, U and Bollow, M and Schulz, C and Fleissner, C and (2003) Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography Clinical Cancer Research, 9, pp. 3047 - 3051.
10. Abildgaard, N and Glerup, H and Rungby, J and Bendix-Hansen, K and Kassem, M and Brixen, K and (2000) Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma European Journal of Haematology, 64, pp. 121 - 129.
11. Fonseca, R and Trendle, M and Leong, T and Kyle, R and Oken, M and Kay, N and (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients British Journal of Haematology, 109, pp. 24 - 29.
12. Jakob, C and Zavrski, I and Heider, U and Brux, B and Eucker, J and Langelotz, C and (2002) Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma European Journal of Haematology, 69, pp. 37 - 42.
13. Hayasaka, A and Iida, S and Ohto, M. (1995) Serum concentrations of the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen in chronic liver disease Clinica Chimica Acta, 238, pp. 85 - 90.
14. Al-Awadhi, A and Olusi, S and Al-Zaid, N and Prabha, K. (1999) Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis The Journal of Rheumatology, 26, pp. 1250 - 1256.
15. Alexandrakis, M and Passam, F and Malliaraki, N and Katachanakis, C and Kyriakou, D and Margioris, A. (2002) Evaluation of bone disease in multiple myeloma: A correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients Clinica Chimica Acta, 325, pp. 51 - 57.
16. Woitge, H and Horn, E and Keck, A and Auler, B and Seibel, M and Pecherstorfer, M. (2001) Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis Clinical Chemistry, 47, pp. 686 - 693.
17. Nawawi, H and Samson, D and Apperley, J and Girgis, S. (1996) Biochemical bone markers in patients with multiple myeloma Clinica Chimica Acta, 253, pp. 61 - 77.
18. Sezer, O and Heider, U and Jakob, C and Zavrski, I and Eucker, J and Possinger, K and Sers, C and Krenn, V. (2002) Immunocytochemistry reveals RANKL expression of myeloma cells Blood, 99, pp. 4646 - 4647.
19. Heider, U and Zavrski, I and Jakob, C and Bangeroth, K and Fleissner, C and Langelotz, C and (2004) Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells Journal of Cancer Research and Clinical Oncology, 130, pp. 469 - 474.